Paris, France and Cambridge, Massachusetts,
USA, November 15, 2018 – NANOBIOTIX
(Euronext: NANO – ISIN: FR0011341205), a late clinical-stage
nanomedicine company pioneering new approaches to the treatment of
cancer, today announces its unaudited revenues for the third
quarter of 2018.
Income Statement for the third quarter
of 2018
In € |
Q3 2018 |
Q2 2018 |
Q1 2018 |
Q3 2017 |
Revenues |
21,816 |
73,304 |
- |
33,018 |
Of which:
LicenseServices |
- 21,816 |
- 73,304 |
- - |
- 33,018 |
Year-to-date income statement for the
nine-months ended September 30th, 2018
In € |
Nine-Months Ended 09/30/2018 |
Nine-Months Ended 09/30/2017 |
Revenues |
95,120 |
91,663 |
Of which:
LicenseServices |
- 95,120 |
146 91,517 |
Activity and results
Total revenue for the third quarter of 2018
amounted to € 21,816. This brings total revenue for the first nine
months of 2018 to € 95,120, which is in line with the Company’s
expectations.
All of the revenues generated by the Company
during the third quarter of 2018 come from services that Nanobiotix
crossed-charged to its partners in accordance with our agreed upon
development program operational activities.
In July 2018, Nanobiotix launched a non-dilutive
financial partnership with the European Investment Bank (EIB) to
boost its research, development and innovation activities. The
financing agreement permits the Company to borrow up to €40 million
in loans from EIB over the next five years subject to the Company’s
achievement of a set of agreed performance criteria. We expect this
financing agreement to enable Nanobiotix to accelerate both the
development of the Company’s NBTXR3 clinical trial in advanced Head
and Neck cancers and to support its European go-to-market
strategy.
In September 2018, Nanobiotix presented an
update on data from its NBTXR3 development program at the
International Conference on Immunotherapy Radiotherapy
Combinations. The presentation included updated data related to the
Company’s follow-up for its Phase I/II clinical trial in advanced
Head and Neck cancers in elderly and frail patients ineligible for
cisplatin or intolerant to cetuximab. The data suggests the
potential of NBTXR3 to impact survival for this advanced cancer
patient population. In addition, the Company
presented data obtained from the immuno biomarker study in its
randomized Phase II/III clinical trial in soft tissue sarcoma. This
data indicated that NBTXR3 activated by radiation therapy could
modulate the antitumor immune response.
Finally, the Company’s in vivo investigation of
NBTXR3’s mode of action inducing distant immune response on CT26
tumoral model produced data that continues to support the rationale
for the use of NBTXR3 activated by radiation therapy to seek to
transform tumors into an in situ cancer vaccine and its potential
use in combination with immunotherapeutic agents.
***Next financial press
release: revenue for Q4 2018 by February 28, 2019
About NBTXR3
NBTXR3 is a first-in-class product designed to
destroy, when activated by radiotherapy:
- tumors through physical cell death
- metastasis due to immunogenic cell death leading to activation
of the immune system
NBTXR3 has a high degree of biocompatibility,
requires one single administration before the whole radiotherapy
treatment and Nanobiotix believes it has the ability to fit into
current worldwide standards of radiation care.
Nanobiotix’s broad clinical program includes 10
patient populations evaluated in 7 clinical trials.
In June 2018, Nanobiotix established human proof
of concept for this first-in-class product in its Soft Tissue
Sarcoma (STS) Phase III clinical trial.
NBTXR3 is actively being evaluated in head and
neck cancer with locally advanced squamous cell carcinoma of the
oral cavity or oropharynx in elderly and frail patients that are
unable to receive chemotherapy or cetuximab and have very limited
therapeutic options. Promising results have been observed from the
ongoing Phase I/II trial regarding the local control of tumors.
Nanobiotix is running an Immuno-Oncology
development program. In the United States, Nanobiotix has received
approval from the U.S. Food and Drug Administration (FDA) to launch
a clinical study of NBTXR3 activated by radiotherapy in combination
with anti-PD1 antibodies in lung, and head and neck cancer patients
(head and neck squamous cell carcinoma and non-small cell lung
cancer).
The other ongoing NBTXR3 trials are treating
patients with liver cancers (hepatocellular carcinoma and liver
metastasis), locally advanced or unresectable rectal cancer in
combination with chemotherapy, head and neck cancer in combination
with concurrent chemotherapy, and prostate adenocarcinoma.
The first market authorization process (CE
Marking) is ongoing in Europe in the STS indication.
About
NANOBIOTIX: www.nanobiotix.com
Incorporated in 2003, Nanobiotix is a leading, late clinical-stage
nanomedicine company pioneering new approaches to significantly
change patient outcomes by bringing nanophysics to the heart of the
cell.
The Nanobiotix philosophy is one rooted in
designing pioneer physical based approaches to bring highly
effective and generalized solutions to address high unmet medical
needs and challenges.
Nanobiotix’s first-in-class, proprietary lead
technology, NanoXray, aims to expand radiotherapy benefits for
millions of cancer patients. Furthermore, Nanobiotix’s
Immuno-Oncology program has the potential to bring a new dimension
to cancer immunotherapies.
Nanobiotix is listed on the regulated market of
Euronext in Paris (Euronext: NANO / ISIN: FR0011341205; Bloomberg:
NANO: FP). The Company’s headquarters are based in Paris, France,
with a U.S. affiliate in Cambridge, MA, and European affiliates in
Spain and Germany.
Contact
Nanobiotix |
Sarah GaubertDirector, Communication & Public
Affairs+33 (0)1 40 26 07 55sarah.gaubert@nanobiotix.com
/contact@nanobiotix.com |
Noël Kurdi Director,
Investor Relations +1 (646) 241-4400 noel.kurdi@nanobiotix.com /
investors@nanobiotix.com |
Ricky Bhajun Investor
Relations Europe +33 (0)1 79 97 29 99 ricky.bhajun@nanobiotix.com /
investors@nanobiotix.com |
Media relations |
|
France -
Springbok ConsultantsMarina
Rosoff+33 (0)6 71 58 00 34marina@springbok.fr |
|
United States –
RooneyPartners Marion Janic +1
(212) 223-4017mjanic@rooneyco.com |
|
|
Disclaimer
This press release contains certain
forward-looking statements concerning Nanobiotix and its business.
Such forward-looking statements are based on assumptions that
Nanobiotix considers to be reasonable. However, there can be no
assurance that the estimates contained in such forward-looking
statements will be verified, which estimates are subject to
numerous risks including the risks set forth in the reference
document of Nanobiotix filed with the French Financial Markets
Authority (Autorité des Marchés Financiers) under number D.17-0470
on April 28, 2017 as well as in its 2017 annual financial report
filed with the French Financial Markets Authority on March 29, 2018
(a copy of which is available on www.nanobiotix.com) and to the
development of economic conditions, financial markets and the
markets in which Nanobiotix operates. The forward-looking
statements contained in this press release are also subject to
risks not yet known to Nanobiotix or not currently considered
material by Nanobiotix. The occurrence of all or part of such risks
could cause actual results, financial conditions, performance or
achievements of Nanobiotix to be materially different from such
forward-looking statements. This press release and the information
that it contains do not constitute an offer to sell or subscribe
for, or a solicitation of an offer to purchase or subscribe for,
Nanobiotix shares in any country. At the moment NBTXR3 does not
bear a CE mark and is not permitted to be placed on the market or
put into service until NBTXR3 has obtained a CE mark.
- 2018_11_15_Nanobiotix_PR-Q3_revenue_2018
Nanobiotix (EU:NANO)
Historical Stock Chart
From Sep 2024 to Oct 2024
Nanobiotix (EU:NANO)
Historical Stock Chart
From Oct 2023 to Oct 2024